Prostate Cancer - Results from #740

The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Jong Chul Park, MD October 23, 2014

Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate, "Beyond the Abstract," by Giovanni Losco, MB ChB(Dist), FRACS(Urol) October 21, 2014

Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines, "Beyond the Abstract," by Lien Spans and Frank Claessens October 16, 2014

Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer, "Beyond the Abstract," by Guoua Shen and Zhiyun Jia October 15, 2014

A transgenic mouse model for early prostate metastasis to lymph nodes, "Beyond the Abstract," by Irwin H. Gelman, PhD October 14, 2014

Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos, "Beyond the Abstract," by Eliza M. Raymundo, MD October 13, 2014

Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer, "Beyond the Abstract," by Helge Taubert, PhD October 9, 2014

Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance, "Beyond the Abstract," by Ignacio F. San Francisco October 8, 2014

A possible link between the use of antipsychotics in schizophrenia and the risk of prostate cancer, "Beyond the Abstract," by Yoram Barak, MD, MHA October 3, 2014

MRI-targeted prostate biopsy: The future of cancer diagnosis? "Beyond the Abstract," by Fergus V. Coakley, MD October 2, 2014

High-intensity focused ultrasound (HIFU): Time-dependent change of blood flow in the prostate posttreatment, "Beyond the Abstract," by Sunao Shoji, MD, PhD September 25, 2014

Nuclear morphometry, epigenetic changes, and clinical relevance in prostate cancer, "Beyond the Abstract," by Robert W. Veltri, PhD and Christhunesa S. Christudass September 9, 2014

Preliminary evaluation of the dosimetric accuracy of the in vivo plastic scintillation detector OARtrac system for prostate cancer treatments, "Beyond the Abstract," by Sam Beddar September 4, 2014

Regular transition zone biopsy during active surveillance for prostate cancer may improve detecting pathological progression, "Beyond the Abstract," by Lih-Ming Wong August 28, 2014

Outcomes of men with prostate cancer where elevated PSA is the sole preoperative intermediate- or high-risk feature, "Beyond the Abstract," by Farzana A. Faisal and Ashley E. Ross August 28, 2014

A therapeutic vaccine for prostate cancer: Immune impact induced by PROSTVAC (PSA-TRICOM), "Beyond the Abstract," by James L. Gulley, MD, PhD August 21, 2014

Looking back at the preclinical discovery of enzalutamide, "Beyond the Abstract," by Yun-Sok Ha, MD, PhD and Isaac Yi Kim, MD, PhD August 19, 2014

Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence, "Beyond the Abstract," by Carlos S. Moreno, PhD August 14, 2014

A systematic literature review of well-designed studies comparing image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer, "Beyond the Abstract," by Jochen Walz August 12, 2014

Health care costs for treatment and for adverse events in prostate cancer patients receiving androgen deprivation therapy, "Beyond the Abstract," by Karen E. Bremner, BSc August 12, 2014

Page 38 of 58